baber/WOPTO huggingface dataset:
Patent JP-H0221785-B2 (JP)
IPC: A23F5/02
Filed: 1986-12-15
Abstract: 1. Process for improving the quality of roasted coffee by the enrichment of raw coffee with saccharide, in which the saccharide is added to the raw coffee in aqueous solution, characterized in that the aqueous solution contains, in addition to the enriching saccharide, an extract of all water-soluble coffee ingredients of the raw coffee, the concentration of the raw-coffee ingredients - in addition to the enriching saccharide - being selected in such a way that the ingredients in the raw coffee on the one hand and in the solution on the other hand are in equilibrium with one another.
Patent JP-H0764848-B2 (JP)
IPC: A61P3/08
Filed: 1986-12-18
Abstract: Blood sugar levels are reduced by administration of novel 4-thienyl-dihydropyridines of the formula   <IMAGE>   in which R1 represents 1 or 2 halogen atoms, or represents straight-chain, branched or cyclic alkyl with up to 8 carbon atoms, R2 represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical which has up to 15 carbon atoms, is optionally interrupted by one or two oxygen atoms, -N-phenyl or -SOn-(n=0, 1 or 2) and is optionally substituted by halogen, phenyl, hydroxyl, cyano, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, pyridyl, piperidino, N-phenylpiperazino, N-methylpiperazino, morpholino or N-benzyl-N-benzyl-N-methyl-amino, R3 represents hydrogen, or represents straight-chain, branched or cyclic alkyl which has up to 6 carbon atoms and is optionally substituted by halogen, hydroxyl, amino or amino-C1-C6-alkoxy, or represents cyano or formyl and R4 represents hydrogen or a straight-chain, branched or cyclic alkyl radical which has up to 10 carbon atoms, is optionally interrupted by one or two oxygen atoms in the chain and is optionally substituted by halogen, cyano, hydroxyl, phenyl, carboxyl, C1-C6-alkoxycarbonyl, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, formyl, piperidino, morpholino or thiomorpholino, or physiologically acceptable salts thereof.
Patent JP-2564245-B2 (JP)
IPC: C12N5/078
Filed: 1993-11-30
Granted: 1996-12-18
Abstract: (1) Leukoregulin (I) in pure form and its biological sub-units are new. It regulates the physiology and growth of malignant tumour cells without affecting the growth of normal cells. (I) directly lyses tumour cells; it suppresses tumour cell proliferation; it enhances the susceptibility of tumour cells to NK cell mediated lysis; it alters tumour cell surface conformation and permeability; and it inhibits the carcinogenic transformation of normal cells. (2) Isolated concd. human (I) having a molecular wt. of 120,000-140,000 and isoelectric focussing points at pH 4.8-5.5 and 7.5-8.3 is new. It is eluted on anion exchange chromatography at 0.07-0.12 M NaCl salt conc. It is partly digested by protease but not by neuraminidase and it produces subunits on dissociation of mol. wt. 30,000-35,000. (3) Biologically active compsn. comprising an effective amt. of (I) is new. (4) Cell producing human (I) and consisting of transformed B cells or hybridoma cells is new. It is obtd. from the peripheral blood of a cancer patient who has been inoculated with a vaccine comprising viable cells from the patient's own tumour, or a culture of the cells. (5) Cells producing human (I) transformed by a transfer vector contg. the gene for (I), or a biologically subunit of it, is new. (6) Monoclonal antibody specific for (I) cell surface receptor is new. (7) Hybridoma producing the monoclonal antibody defined above is new. (8) (I) or its subunit is used in a method for treating tumour cells in tissue, the method comprising the ex-vivo exposure of tumour cells. Esp. viable bone marrow cells for use in reconstituting a patient's bone marrow are first exposed to (I) or its subunit.
Patent JP-H0774165-B2 (JP)
IPC: A61K47/12
Filed: 1989-11-21
Abstract: Pharmaceutical product containing  (a) a compound with antibacterial activity, and (b) an effective amount of an absorption-promoting 2-component system which contains as first component (b 1) an ether composed of a C6-C18-alcohol and polyoxyethylene glycol and as second component either (b 2-1) a polyoxyethylene glycol C6-C18-carboxylic acid glyceride ester, or (b 2-2) a C6-C18-carboxylic acid or a pharmaceutically utilisable salt thereof, or (b 2-3) an ester composed of two or more C6-C18-carboxylic acids, glycerol and a polyoxyethylene glycol.
Patent JP-H0768464-B2 (JP)
IPC: C08K9/06
Filed: 1989-11-24
Abstract: The invention relates to a process for rendering particulate solids containing Si-OH groups hydrophobic which comprises reacting a water repellent containing an organo-silicon compound with particulate solids containing Si-OH groups with simultaneous mechanical loading of the reaction mixture, in which from 5 to 50 percent by weight of the particulate solids containing Si-OH groups are used, based on the total weight of the reaction mixture containing particulate solids and water repellent, and the use of the resultant hydrophobic particulate solids in compositions containing diorganopolysiloxanes, which can be cured to form elastomers.
Patent JP-3106020-B2 (JP)
IPC: B41J3/407
Filed: 1992-11-20
Granted: 2000-11-06
Abstract: PURPOSE:To obtain a label printer whose action modes are set via a host apparatus. CONSTITUTION:A label printer is provided with a printing section which prints image data input from a computer to which the label printer is connected, and the operation mode of the label printer is set by controls of the computer either to peel-off issue mode or continuous issue mode. In peel-off issue mode, the label printed by the printing section is issued after peeled off from a label sheet, and in continuous issue mode, the label is issued without peeled off from the label sheet. The label printer is provided with a set switch 18 by which operation mode of the label printer is set and a selector by which either the set value of operation mode by the computer or the set value of operation mode by the set switch 18 is selected.
Patent JP-4472073-B2 (JP)
IPC: H05B33/10
Filed: 1999-11-26
Granted: 2010-06-02
Abstract: Reducing the manufacturing cost of an EL display device and an electronic device furnished with the EL display device is taken as an objective. A textured structure in which projecting portions are formed on the surface of a cathode is used. External stray light is diffusely (irregularly) reflected by the action of the projecting portions when reflected by the surface of the cathode, and therefore a defect in which the face of an observer or the surrounding scenery is reflected in the surface of the cathode can be prevented. This can be completed without using a conventionally necessary high price circular polarizing film, and therefore it is possible to reduce the cost of manufacturing the EL display device. <IMAGE>
Patent JP-H07113065-B2 (JP)
IPC: F02K9/34
Filed: 1988-10-14
Abstract: A fiber/resin composite whose resin phase is formed by at least initial actinic radiation curing of a resin composition comprising an actinic radiation curable first resin component and a second resin component which is non-cured under curing conditions effective for the first resin component. The actinic radiation exposure of the fiber/resin composition effects curing of the first resin component to immobilize the composite and impart structural integrity thereto, whereby the composite may be handled, packaged, or further processed. Filament wound, braided, and pultruded articles are described, together with associated methods for forming such articles by filament winding, braiding and pultrusion. As a specific embodiment, a solid fuel rocket motor is disclosed comprising a solid fuel body in a filament wound fiber-resin composite casing formed by filament winding of the solid fuel body with resin-impregnated filament or rovings thereof.
Patent JP-3705806-B2 (JP)
IPC: A61P25/00
Filed: 1993-09-28
Granted: 2005-10-12
Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
Patent JP-4205159-B2 (JP)
IPC: C12N15/63
Filed: 1994-06-07
Granted: 2009-01-07
Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID No:1) peptide corresponding to amino acids 638 to 673 of the HIV-1 LAI  gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Patent JP-3206602-B2 (JP)
IPC: C07F9/655
Filed: 1991-03-01
Granted: 2001-09-10
Abstract: PCT No. PCT/CH91/00049 Sec. 371 Date Oct. 25, 1991 Sec. 102(e) Date Oct. 25, 1991 PCT Filed Mar. 1, 1991 PCT Pub. No. WO91/13895 PCT Pub. Date Sep. 19, 1991.The invention is concerned with a process for the manufacture of ascorbyl phosphates, namely of phosphates of the formula   <IMAGE> I  wherein Mk(+) denotes a cation, k(+) denotes the valency and m denotes the equivalents, with the proviso that the product from k.m=3, by phsophorylating ascorbic acid. k is 1 to 3, especially 1 or 2. The process comprises using pre-formed sodium (or potassium) dichlorophosphate as the phosphorylating reagent, adding ascorbic acid to this pre-formed phosphorylating reagent in aqueous solution, especially at pH values between about 11.0 and about 13.0, in the presence of a water-soluble trialkylamine as the catalyst and at temperatures between about +10 DEG  C. and about -8 DEG  C., especially at temperatures below 0 DEG  C., and, if desired, trans-salting the I which is obtained as the sodium (or potassium) salt and/or, if desired, purifying via an amine salt.
Patent JP-3087907-B2 (JP)
IPC: C08J7/046
Filed: 1991-02-15
Granted: 2000-09-18
Abstract: Improvements to the polymerase chain reaction (PCR), a process for in vitro enzymatic amplification of specific nucleic acid sequences, can be achieved by changing the way that PCR reagents are mixed and the enzymatic reaction is started and by the replacement of mineral oil, commonly used as a vapor barrier to minimize solvent evaporation, by a grease or wax. The use of such mixtures allows for the delay of reagent mixing until the first heating step of a PCR amplification, thereby reducing the enzymatic generation of nonspecific products which occurs when a complete mixture of PCR reagents, with or without test sample, stands at room temperature or below. These mixtures increase the shelf-life of PCR reagents and increase protection of the laboratory environment against contamination by PCR product.
Patent JP-2594804-B2 (JP)
IPC: B01J23/26
Filed: 1987-08-07
Granted: 1997-03-26
Abstract: A chromium-contg. tin oxide catalyst compsn. (A) comprises the prod. obtd. by impregnating tin (IV) oxide (SnO2) with chromium (VI) oxide (CrO3), and calcining the impregnated prod. A catalytic converter for vehicle exhaust system comprises catalyst (A). A method for (a) the catalytic oxidn. of carbon monoxide and/or (b) the catalytic oxidn. of hydrocarbons and/or (c) the catalytic redn. of nitrogen oxides in a gaseous medium comprising contacting the latter with catalyst (A).
Patent JP-3923534-B2 (JP)
IPC: G01N33/532
Filed: 1997-07-08
Granted: 2007-06-06
Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.
Patent JP-2862675-B2 (JP)
IPC: A61P25/20
Filed: 1994-05-19
Granted: 1999-03-03
Abstract: PCT No. PCT/IB94/00111 Sec. 371 Date Jan. 18, 1996 Sec. 102(e) Date Jan. 18, 1996 PCT Filed May 19, 1994 PCT Pub. No. WO95/03281 PCT Pub. Date Feb. 2, 1995This invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the application. These compounds are CCK-B receptor antagonists and are useful in the treatment and prevention of central nervous system and gastrointestinal disorders.    <IMAGE>  (I)
Patent JP-3647459-B2 (JP)
IPC: A61B5/055
Filed: 1995-07-26
Granted: 2005-05-11
Abstract: A technique has previously been described for generating optimal RF pulse sequences using finite impulse response filter techniques to calculate the Fourier series which would yield the desired z and xy magnetizations in a magnetic resonance imaging device. Such a technique is now extended to allow for control of the input pulse shape as well as the frequency response. Since the peak power is limited by the amplifier power and the total energy of the pulse is limited by the specific absorption rate (SAR) of the tissue or sample, it is desired to limit the peak power and total energy of the input pulse without degrading the resulting excitation. This is accomplished by recognizing that the total energy of the pulse is encoded in the lowest order Fourier series coefficients of the frequency response and then specifying the total energy of the pulse as a design parameter to the RF pulse synthesis algorithm. Peak power of the pulse may also be limited by selecting roots for  beta ( omega ), where Mz( omega )=+543  alpha ( omega )+543 2-+543  beta ( omega )2, which leads to pulses with variable phase yet do not change the overall frequency response. By appropriately selecting  alpha ( omega ) and  beta ( omega ), a hard pulse sequence is generated which serves as the basis for a shaped pulse which meets the desired constraints on the input pulse shape.
Patent JP-2839950-B2 (JP)
IPC: G06T7/20
Filed: 1990-04-18
Granted: 1998-12-24
Abstract: A motion vector for motion-compensated prediction in an inter-frame differential video coder is derived by comparing each block in a row of a current frame with the corresponding region, and positionally shifted regions, of a previous frame. The blocks are processed row by row, and scanned in a vertical column-by-column scan with each of the shifted regions. Two or more rows may be processed at a time. For a +/-7 pixel search, two or four comparison processors are provided, one (or one pair) processing odd-numbered blocks and the other (or other pair) processing even-numbered blocks. For a +/-15 pixel search, four or eight processors are provided. The vertical scan is provided using a serial FIFO store including eight 8 tap SIPO sections.
Patent JP-4116072-B2 (JP)
IPC: G01N33/576
Filed: 1993-08-27
Granted: 2008-07-09
Abstract: Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.
Patent JP-3241723-B2 (JP)
IPC: C07C255/21
Filed: 1992-10-05
Granted: 2001-12-25
Abstract: An improved process for the preparation of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate is described where a halo hydroxyester or other activated dihydroxyester is converted in two steps to the desired product.
Patent JP-3237848-B2 (JP)
IPC: G01N21/78
Filed: 1993-09-02
Granted: 2001-12-10
Abstract: The invention relates to a process for making a test element, such as an analytical test element. Compositions of matter, such as analyte specific receptors, are treated to carry a charge. These are then applied to test carriers treated to carry a charge opposite that of the composition of matter. Interaction of charge fixes the composition of matter to the test element.
Patent JP-2849657-B2 (JP)
IPC: B23K26/362
Filed: 1993-09-23
Granted: 1999-01-20
Abstract: PCT No. PCT/EP93/02577 Sec. 371 Date Apr. 28, 1995 Sec. 102(e) Date Apr. 28, 1995 PCT Filed Sep. 23, 1993 PCT Pub. No. WO94/07422 PCT Pub. Date Apr. 14, 1994In order to render possible the ablation to different depths in a process for correcting the shape of a lens in which the surface of the lens is acted upon by the radiation of a pulsed radiation source through a shutter in specific regions exposed by the shutter and thereby removing material from the lens by the radiation effect during the impingement of each radiation pulse, wherein the radiation is concentrated in a bundle of rays, the cross section of which is smaller when striking the lens surface than that of the lens surface exposed by the shutter, and wherein the bundle of rays is moved such that the entire lens surface exposed by the shutter is irradiated by radiation pulses consecutively impinging on the lens surface, it is suggested that the bundle of rays is moved between successive radiation pulses only to such an extent that the regions of the lens surface struck by the radiation pulses consecutively impinging on the lens surface partially overlap. A device is also suggested for performing this process.
Patent JP-2706568-B2 (JP)
IPC: C12Q1/68
Filed: 1991-04-15
Granted: 1998-01-28
Abstract: Methods for identifying oligonucleotides capable of hybridizing with nucleic acid of an infectious agent are disclosed. In accordance with preferred embodiments, oligonucleotides capable of antisense interaction with RNA which is significant to a bodily state of an animal or which is contributory to a diseased state is identified. Therapeutic, diagnostic and research methods and compositions employing such oligonucleotides are provided. Prior knowledge of the sequence of nucleic acid in the infectious agent is generally not required.
Patent JP-3228936-B2 (JP)
IPC: C09D201/00
Filed: 1993-11-03
Granted: 2001-11-12
Abstract: Compositions and a method are described which possess utility for the application of a corrosion-resistant surface to an object of interest. The composition of the subject invention includes a polymeric solution, emulsion or dispersion, and a compatible dispersion which are combined with water to form a bath. The objects of interest to be coated are thereafter quenched in the bath.
Patent JP-3813983-B2 (JP)
IPC: C07D401/12
Filed: 1994-10-24
Granted: 2006-08-23
Abstract: 5-Membered ring heterocycle of the formula I,in which D includes a COOR15, CON(CH3)R15 or CONHR15 radical and R15 includes a 6-24 member bicyclic or tricyclic radical, compositions, preparation and use as inhibitors of thrombocyte aggregation, metastasization of carcinoma cells, binding of osteoclasts to bone surfaces and for the treatment of tromboses.
Patent JP-4117023-B2 (JP)
IPC: C12P21/02
Filed: 1993-12-03
Granted: 2008-07-09
Abstract: The present invention relates to a system for replication and encapsidation of recombinant DNA fragments into virus particles comprised of adenovirus associated viral (AAV) capsid proteins. The invention provides a means of obtaining recombinant viral stocks that may be used to treat patients suffering from genetic diseases.
Patent JP-3117719-B2 (JP)
IPC: C07D231/38
Filed: 1993-04-27
Granted: 2000-12-18
Abstract: PCT No. PCT/GB93/00869 Sec. 371 Date Aug. 23, 1993 Sec. 102(e) Date Aug. 23, 1993 PCT Filed Apr. 27, 1993 PCT Pub. No. WO93/22260 PCT Pub. Date Nov. 11, 1993.Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilisers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabiliser and dye.
Patent JP-3985076-B2 (JP)
IPC: B65D8/04
Filed: 1996-11-04
Granted: 2007-10-03
Abstract: A particular object of the invention is to provide a telescope-type capsule, e.g., for pharmaceutical use or the like, consisting of a cap and a body, the cap having four to six elongated, flat protrusions on its inner wall with a depth of from 30 to 100  mu m, preferably 50 to 80  mu m, and a length of 1.5 to 3 mm, and a narrowing positioned between the closed end and cylindrically shaped part of the capsule. The narrowing has an area with smaller inclination relative to the capsule axis and an area with stronger inclination which is disposed further away from the open end of the cap than the area with smaller inclination and has a width of 2 to 3 mm and an inclination of 0.03 to 0.07 mm/mm, preferably 0.04 to 0.06 mm/mm. A locking ring with a depth of from 30 to 160  mu m, preferably 140 to 120  mu m and a width of from 0.8 to 1.2 mm is provided on said narrowing. The body comprises likewise a locking ring, the counter locking ring, which matches the locking ring of the cap and has a depth of 25 to 70  mu m and a width of 0.7 to 1.3 mm. Furthermore, at its open end the body is provided with an area of reduced diameter formed by a circular shaped ring with a depth of 10 to 60  mu m and a width of 0.8 to 1.4 mm and a wider ring of symmetrical or asymmetrical cross-sectional profile to fit the elongated protrusions.
Patent JP-3408813-B2 (JP)
IPC: G01L13/02
Filed: 1994-03-09
Granted: 2003-05-19
Abstract: PCT No. PCT/DE94/00262 Sec. 371 Date Nov. 28, 1995 Sec. 102(e) Date Nov. 28, 1995 PCT Filed Mar. 9, 1994 PCT Pub. No. WO94/21992 PCT Pub. Date Sep. 29, 1994A pressure difference measurement transducer with an inner housing divided into two parts transversely to its longitudinal axis has a central diaphragm bearing a pressure sensor clamped between the two housing sections. One housing section contains an electric lead-through in a bore, an external extension of which lies in an enlarged part of the bore. To simplify the electric lead-through in the manufacture of such a measurement transducer, the bore is arranged parallel to the longitudinal axis of the measurement transducer. At its end towards the other housing section the bore has an enlarged section and at its end away from the other housing section it becomes an outwardly directed transverse bore.
Patent JP-4376318-B2 (JP)
IPC: A24D3/10
Filed: 1997-01-08
Granted: 2009-12-02
Abstract: A cigarette is provided with a filter comprising a filter element of water-disintegratable paper. The paper is water swellable and/or the filter element comprises a water swellable agent. Tipping which interattaches the filter to the tobacco rod of the cigarette is anchored by means of water susceptible adhesive. Thus when the cigarette comes into contact with sufficient water, the filter element swells and the tipping opens away from the filter. This facilitates disintegration of the water-disintegratable paper.